iCAD exhibiting new updates and enhanced Xoft platform at ASTRO including single-fraction IORT solution
Press releases may be edited for formatting or style | September 17, 2019
Rad Oncology
NASHUA, N.H. and CHICAGO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will showcase its latest advancements for the Xoft® Axxent® Electronic Brachytherapy (eBx®) System®, including new and updated x-ray sources and the full suite of applicators for existing and emerging applications in the Xoft exhibition booth (#4205) at the American Society for Radiation Oncology (ASTRO) Annual Meeting in Chicago at McCormick Place West from September 15-18, 2019. iCAD will also be concurrently exhibiting at the Society for Radiation Oncology Administrators (SROA) Annual Meeting at the Hilton Chicago from September 15-18, 2019.
“The Xoft System is a transformative radiation treatment option that offers a targeted, single-fraction therapy for early-stage breast cancer, along with the added versatility and cross-functionality to treat other types of cancers, such as nonmelanoma skin cancers and gynecological cancers,” according to Gary Proulx, MD, medical director and radiation oncologist at Exeter Hospital and featured expert speaker at iCAD’s “Evening of eBx” event scheduled to take place during the meeting. “As cancer treatment becomes increasingly targeted and value-based, iCAD’s Xoft System continues to be an established trailblazer in this revolutionary trend towards more personalized cancer treatment.”
Leading experts will be available in the Xoft booth throughout ASTRO and SROA to discuss their clinical experience using the technology across various cancer types. The Xoft System will be available for demonstration in the booth at ASTRO and new and updated advancements will be unveiled, including those highlighted below:
New applicators for minimally-invasive robotic surgery, including prostate, as well as an advanced prototype for early-stage rectal cancers
Extended-length balloon applicators, now available in 25 mm and 50 mm lengths, which offer added versatility and the potential for additional applications for Xoft eBx in different areas of the body
Extended-life x-ray sources, featuring a ten-fold increase in treatment times, which offer time-saving benefits for clinicians and enhance efficiency
The full suite of currently-available eBx applicators, including those with established data for early-stage breast cancer, gynecological cancers, nonmelanoma skin cancers, and most recently, brain cancers
|
|
|
You Must Be Logged In To Post A Comment
|
